Joint pain
Conditions
Interventions
Groups
Participants will be allocated in two groups.
Group 1 - 18 patients
You will be submitted to treatment with the association of hydroxychloroquine (400mg, 1 tablet/day for 3 months) with pregaba
Drug
E03.091
Sponsors
Rodrigo Souza Rodrigues
Rodrigo Souza Rodrigues
Eligibility
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 35 participants will be included aged 18 to 100 years old; Both sexes; With chronic illness (more than 3 months); Individuals with arthralgia after chikungunya, previously diagnosed with sorology positive for CHIK; Individuals with pain upper than 4
Exclusion criteria
Exclusion criteria: Non-inclusion criteria patient with sorologies for CHIK with negative IGG and positive IGM; FR (rheumatoid factor) and FAN (antinuclear factor) positive in high values; Cognitive dysfunction (unable to understand the explanations); Psychiatric illness; Drug user; Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The present study aims to assess the decrease in pain intensity with the use of pregabalin associated with hydroxychloroquine, compared with hydroxychloroquine alone for patients with chikungunya. Pain assessment will be on the verbal numeric scale from 0 to 10, before the start of the medication and after 2weeks, 1m, 2m and 3m. | — |
Secondary
| Measure | Time frame |
|---|---|
| An improvement in quality of life is expected due to improved pain scores both in the control group and in the intervention group, but with greater intensity in the intervention group, which will be assessed through the WHOQOL-100 questionnaire which will be applied at the beginning and at the end of the study ;Assess the occurrence of side effects of the studied drugs and supplemental analgesics | — |
Countries
Brazil
Contacts
Public ContactRodrigo Rodrigues
Rodrigo Souza Rodrigues
Outcome results
None listed